Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472220 | 0.98 | L3MBTL1 (0.50) | PARP1LMNAL3MBTL1MAPTTDP1 | |
| SCHEMBL1641363 | 0.95 | PARP1 (0.50) | PARP1LMNAL3MBTL1MAPTTDP1 | |
| SCHEMBL3357671 | 0.88 | PARP1 (0.53) | PARP1LMNAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL7821163 | 0.83 | LMNA (0.67) | PARP1LMNAL3MBTL1MAPTTDP1 | |
| SCHEMBL17952793 | 0.83 | HSD17B3 (0.56) | LMNAL3MBTL1MAPTTDP1ALDH1A1 | |
| SCHEMBL3844203 | 0.83 | HSD17B3 (0.56) | LMNAL3MBTL1MAPTTDP1ALDH1A1 | |
| SCHEMBL3896481 | 0.83 | OGG1 (0.58) | PARP1LMNAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL3455824 | 0.81 | PARP1 (0.50) | PARP1LMNAL3MBTL1MAPTTDP1 | |
| SCHEMBL7826009 | 0.81 | LMNA (0.60) | PARP1LMNAL3MBTL1MAPTTDP1 | |
| SCHEMBL5660410 | 0.81 | ERCC5 (0.54) | PARP1LMNAL3MBTL1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099760-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-8293732-B2 | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-23 | — | — | US | disclosed |
| US-20100029679-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2010-02-04 | — | — | US | disclosed |
| CN-101547905-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| CN-1671386-A | Substituted anilinic piperidines as MCH selective antagonists | LUNDBECK & CO AS H (DK) | 2005-09-21 | — | — | CN | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | PARP1 4441/4885LMNA 4566/4885L3MBTL1 3754/4885 |
| US-20100029679-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB7, NDUFB5 | PARP1 3935/4885LMNA 2887/4885L3MBTL1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.